Hyaluronic Acid Nanomaterials in Targeted Drug Delivery for Cancer Therapy

Abstract

Hyaluronic acid and the CD44 receptor have been the subject of 3D interaction and molecular analysis that has revealed crucial residues, binding specificity, stabilizing relationships, and structural insights within the complex. The analysis has focused on amino acid interactions. It is a crucial field of study with both fundamental and applied consequences because this understanding not only illuminates the molecular mechanisms directing their interaction but also shows promise for future therapeutic approaches. The new methods cover a variety of strategies, such as creating highly focused treatments, combining treatments with other well-known techniques like immunotherapy and chemotherapy, and moving toward customized medicine. Combining state-of-the-art nanotechnology with hyaluronan-based pharmaceuticals could improve lung cancer therapy's precision, bioavailability, and drug delivery. Clinical trials will be essential in proving these medicines' safety and effectiveness so that they may be incorporated into standard cancer treatment. Moreover, investigating immune regulation via hyaluronan may open up new avenues for bolstering the body's defenses against  cancer. With a calculated binding energy score of -6.70, the interaction between hyaluronan and the CD44 protein receptor was observed to be remarkably strong and favorable, suggesting a robust connection. This highlights the potential for utilizing hyaluronic nanomaterials to facilitate the targeted delivery of commercially available cancer drugs to specific cancer sites.